The Role of Biomarkers in Immunotherapy Selection for mUC

Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

First-line maintenance with avelumab in locally advanced or metastatic urothelial carcinoma yields efficacy that appears consistent between clinical and real-world settings.

Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

An exploratory analysis indicates that overall survival did not improve with the use of single-agent atezolizumab in untreated locally advanced or metastatic urothelial cancer.

Pembrolizumab appears to achieve antitumor activity in terms of disease-free survival in patients with Bacillus calmette-guerin–unresponsive, papillary high–risk, non-muscle invasive bladder cancer.